These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 21742900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H.
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [Abstract] [Full Text] [Related]

  • 3. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
    Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, Barr JT, Jones JP, Halladay JS.
    Drug Metab Dispos; 2015 Jun; 43(6):908-15. PubMed ID: 25845827
    [Abstract] [Full Text] [Related]

  • 4. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, Marsters JC, Plise E, Rudewicz PJ, Robarge K, Shin Y, Wong S, Zhang C, Khojasteh SC.
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [Abstract] [Full Text] [Related]

  • 5. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.
    Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Eigenbrot C, Gallion S, Johnson AR, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Wang X, Wong H, Xiong JM, Xu J, Yu C, Zhao Z, Currie KS.
    Bioorg Med Chem Lett; 2016 Jan 15; 26(2):575-579. PubMed ID: 26675441
    [Abstract] [Full Text] [Related]

  • 6. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
    Young WB, Barbosa J, Blomgren P, Bremer MC, Crawford JJ, Dambach D, Gallion S, Hymowitz SG, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Maurer B, Mitchell SA, Ortwine DF, Di Paolo J, Reif K, Scheerens H, Schmitt A, Sowell CG, Wang X, Wong H, Xiong JM, Xu J, Zhao Z, Currie KS.
    Bioorg Med Chem Lett; 2015 Mar 15; 25(6):1333-7. PubMed ID: 25701252
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS, Hatch HL, Kosea F, Nguyen HT, Choo EF, McClure KF, Taylor TJ, Henne KR, Kuperman AV, Dombroski MA, Letavic MA.
    Biopharm Drug Dispos; 2006 Nov 15; 27(8):371-86. PubMed ID: 16944451
    [Abstract] [Full Text] [Related]

  • 9. Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitation.
    Shin YG, Jones SA, Murakami SC, Liu L, Wong H, Buonarati MH, Hop CE.
    Biomed Chromatogr; 2012 Nov 15; 26(11):1444-51. PubMed ID: 22311651
    [Abstract] [Full Text] [Related]

  • 10. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
    Kumar GN, Jayanti V, Lee RD, Whittern DN, Uchic J, Thomas S, Johnson P, Grabowski B, Sham H, Betebenner D, Kempf DJ, Denissen JF.
    Drug Metab Dispos; 1999 Jan 15; 27(1):86-91. PubMed ID: 9884314
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS, Maurer TS, Kalgutkar AS, Royer LJ, Francone OL, Winter SM, Terra SG, Chen D, Gao X.
    Xenobiotica; 2009 Oct 15; 39(10):766-81. PubMed ID: 19622022
    [Abstract] [Full Text] [Related]

  • 12. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
    Choo EF, Driscoll JP, Feng J, Liederer B, Plise E, Randolph N, Shin Y, Wong S, Ran Y.
    Xenobiotica; 2009 Sep 15; 39(9):700-9. PubMed ID: 19552528
    [Abstract] [Full Text] [Related]

  • 13. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L, Pang J, Plise EG, Chou B, Halladay JS, Olivero AG, Rudewicz PJ, Tian Q, Wong S, Zhang X.
    Xenobiotica; 2011 Dec 15; 41(12):1088-99. PubMed ID: 21838594
    [Abstract] [Full Text] [Related]

  • 14. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X.
    Drug Metab Dispos; 2012 Sep 15; 40(9):1785-96. PubMed ID: 22696419
    [Abstract] [Full Text] [Related]

  • 15. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O'Mahony A, Owens TD, Lou Y, Hill RJ, Narula S, DeMartino J, Fine JS.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):90-103. PubMed ID: 22228807
    [Abstract] [Full Text] [Related]

  • 16. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.
    Lang D, Freudenberger C, Weinz C.
    Drug Metab Dispos; 2009 May 15; 37(5):1046-55. PubMed ID: 19196846
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
    Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, Fairbrother WJ.
    Drug Metab Dispos; 2013 Dec 15; 41(12):2104-13. PubMed ID: 24041744
    [Abstract] [Full Text] [Related]

  • 19. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
    Dean BJ, Chang S, Silva Elipe MV, Xia YQ, Braun M, Soli E, Zhao Y, Franklin RB, Karanam B.
    Drug Metab Dispos; 2007 Feb 15; 35(2):283-92. PubMed ID: 17132765
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.